Navigation Links
REMOXY(R) NDA Update
Date:7/7/2009

CUPERTINO, Calif., July 7 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) have announced that King met with the Food and Drug Administration (FDA) on July 2, 2009 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for REMOXY(R). According to King Pharmaceuticals and Pain Therapeutics, the outcome of the meeting last week provided King with a clear path forward to resubmit the REMOXY NDA and to address all FDA comments in the Complete Response Letter.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

According to the King Pharmaceuticals / Pain Therapeutics press release, King now anticipates the resubmission of the NDA could occur mid-year 2010. King believes that the rate limiting step is the generation of six-month stability data, and no new clinical trials are required. King has stated that it remains committed to the development and commercialization of REMOXY and looks forward to working closely with the FDA toward approval of the product.

REMOXY, based on DURECT's ORADUR(TM) technology, is an investigational drug that is a unique, controlled release formulation of oxycodone for moderate-to-severe chronic pain designed to reduce potential risks of unintended use. In mid-2008, an NDA for REMOXY was accepted by the FDA and was granted Priority Review. In December 2008, Pain Therapeutics received a Complete Response Letter from the FDA. Subsequent to the receipt of the Complete Response Letter, King assumed full control of all activities related to the development of REMOXY.

About ORADUR(TM) Technology

ORADUR is a proprietary technology designed to transform short-acting oral capsule dosage forms into sustained release oral products, with the added benefit of being less prone to abuse (e.g. by crushing or alcohol or water extraction) than other controlled release dosage forms on the market today.

Corporate Relationships

In December 2002, DURECT licensed to Pain Therapeutics, Inc. the right to develop and commercialize on a worldwide basis REMOXY and other oral sustained release drug candidates using the ORADUR technology which incorporate four specified opioid compounds. Under the license agreement, DURECT is reimbursed for formulation and other work performed under its agreement, and will receive additional payments if certain development and regulatory milestones are achieved with respect to the licensed drug candidates. In addition, if commercialized, DURECT will receive royalties for REMOXY and the other licensed drug candidates of between 6.0% to 11.5% of net sales of the drug candidate depending on sales volume as well as a mark-up on DURECT's supply of key excipients used in the manufacture of the licensed drug candidates. Pain Therapeutics sublicensed the commercialization rights of REMOXY and other licensed drug candidates to King Pharmaceuticals in November 2005.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding REMOXY its potential attributes and statements related to plans by Pain Therapeutics and King Pharmaceuticals for resubmission of the REMOXY NDA, including the contents and timing of such resubmission, the generation of stability data as described above, the potential of FDA approving the REMOXY NDA, the timing and content of any potential update to be provided by Pain Therapeutics and King, as well as the potential royalty and other payments that may be received by DURECT from REMOXY and other described products are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the potential that the REMOXY NDA resubmission may not adequately address all of FDA's concerns, the potential that FDA may not grant regulatory approval of REMOXY, difficulties or delays in the development, testing, regulatory approval, production and commercialization of REMOXY, and unexpected adverse side-effects or inadequate therapeutic efficacy of REMOXY that could slow or prevent product approval or market acceptance (including the risk that current and past results of clinical trials and tests are not necessarily indicative of future results of clinical trials and tests). Further information regarding these and other risks is included in DURECT's Form 10-Q dated May 7, 2009 under the heading "Risk Factors."


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
2. FDA Updates Prescription Guidelines for Blood Thinner
3. PreMD Provides Update on 510(k) Application for PREVU(x) POC
4. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
5. PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County
6. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
7. Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
8. Update on Jill Finley Story, Coma Survivor
9. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
10. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
11. Updated Brochure on Gynecologic Cancer Treatments Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Cincinnati, OH (PRWEB) , ... December 08, 2016 ... ... offering insurance and financial planning services from offices headquartered in Hamilton County, is ... animal rescue LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, ... and around the greater Phoenix metropolitan region, is announcing a charity event to ... of the Homeless Youth Connection is to promote community awareness of the ongoing ...
(Date:12/8/2016)... Louis, MS (PRWEB) , ... December 08, 2016 , ... ... that serve commercial and residential clients in and around the Hancock County area, is ... for the Hancock County Food Pantry. , The Hancock County Food Pantry has worked ...
(Date:12/8/2016)... ... December 08, 2016 , ... Bill Mull ... business owners in and around central Kansas, is joining the Youth Horizons organization ... the region. , Headquartered in Wichita, Youth Horizons works to empower area children ...
(Date:12/7/2016)... ... December 07, 2016 , ... Students ... have the unique opportunity to get hands-on experience in an emergency medical simulation, ... immersive experience to gain invaluable, real-life medical skills that are critical success in ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Texas , Dec. 8, 2016 ... program that brings leading-edge laboratory services and management ... United States , allowing more doctors and ... health care management solutions. Logo - ... Hospital systems, under pressure to contain ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch die CFDA sowie ... – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the Chinese Congress ... Union Hospital ...
(Date:12/8/2016)... 8, 2016 Dignitana, a world leader in ... Boa® Technology, creator of the award-winning, patented Boa® system, ... with the DigniCap® scalp cooling system. DigniCap® was cleared ... 2015, and is the first medical scalp cooling device ... cooling system features a patented tight-fitting silicone cooling cap ...
Breaking Medicine Technology: